To support genomic researchers, Wolters Kluwer, Health has expanded Ovid® with SRI International’s BioCyc™, a collection of more than 20,000 organism-centric Pathway/Genome Databases (PGDBs) and bioinformatics software tools.
Advances in sequencing technologies and bioinformatics have resulted in a deluge of genetic sequence data that is being used to enhance the understanding of living systems. Additionally, falling costs and faster turnaround times enable academic, non-profit, commercial, and government researchers to use genetic data in drug discovery, agriculture, biotechnology, and other fields.
By adding BioCyc access to Ovid, Wolters Kluwer enables researchers to take advantage of this genomic information and more easily fulfil the promise it holds for clinical and academic research. Users can: Find detailed information about the biology of the organisms in its databases essential for basic biomedical research; Analyse transcriptomics and metabolomics data in a pathway context; Determine how micro-organisms interact with their hosts to cause disease; Discover how to engineer micro-organisms to produce chemicals of industrial importance; and Develop novel approaches to disease diagnostics, prevention, and safe and effective drug discovery.
With access to BioCyc's PGDBs and software-based tools on Ovid's platform, researchers can easily take advantage of the latest pathway and genomics data developments. BioCyc is a natural fit for omics researchers. The Ovid platform's breadth is ideally suited for the fast-evolving, multi-disciplinary research that combines genomics, epigenomics, transcriptomics, proteomics, metabolomics, and other fields.
Click here to read the original press release.
